Clinical Trial Update: A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a 36-week refill regimen of the Port Delivery System with ranibizumab versus aflibercept treat-and-extend in neovascular age-related m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Port Delivery System with ranibizumab (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: WITHDRAWN